Management of the antiphospholipid syndrome

Current Rheumatology Reports

Volumn 8, Issue 2, 2006, Pages 114-120

  DeMarco, Paul ^b   Singh, Inderprit ^b   Weinstein, Arthur ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL FEATURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MICROTHROMBUS; OBSTETRIC CARE; PATHOGENESIS; PREGNANCY; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; VASCULAR DISEASE; VEIN THROMBOSIS; BLOOD; BLOOD CLOTTING; DRUG EFFECT; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; HUMANS; THROMBOSIS; TREATMENT OUTCOME;

EID: 33646941104     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0051-1     Document Type: Review

References (46)

1. Petri M: Clinical and management aspects of the antiphospholipid antibody syndrome. In Dubois Lupus, edn 6. Edited by Wallace D, Fahn B. Philadelphia: Lippincott Williams & Wilkins; 2002:1093-1128.
2. Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 1999, 42:1309-1311.
3. Sanna G, Bertolaccini ML, Cuadrado MJ, et al.: Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003, 42:200-213.
4. Levine JS, Branch W, Rauch J, et al.: The antiphospholipid syndrome. N Engl J Med 2002, 346:752-763. Exhaustive and excellent review of the APS which also includes detailed discussion of differential diagnosis and different clinical manifestations.
5. Petri M: Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000, 15:145-151.
6. De Groot PG, Derksen RHWM: Pathophysiology of antiphospholipid antibodies. Neth J Med 2004, 62:267-272.
7. Tenedios F, Erkan D, Lockshin MD: Cardiac involvement in the antiphospholipid syndrome. Lupus 2005, 14:691-696. Discussion of various cardiac manifestations of aPL including valvular abnormalities and review of literature regarding management.
8. Karp DR: Complement and systemic lupus erythematosus. Curr Opin Rheumatol 2005, 17:538-542.
9. Gomez-Puerta JA, Martin H, Amigo MC, et al.: Long-term follow up in 128 patients with primary antiphospholipid syndrome. Medicine 2005, 84:225-230.
10. Ramos-Casals M, Campoamor MT, Chamorro A, et al.: Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004, 13:777-783.
11. Grion-Gonzalez JA, Del Rio EG, Rodriguez C, et al.: Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody. Prospective analysis of 404 individuals. J Rheumatol 2004, 31:1560-1567. Described initial presentation and prospective follow-up of 404 patients of which 226 had primary or secondary APS, the rest were asymptomatic carriers of aPL. Good description of initial presentation and risk factors identified during thrombotic events. Also shows the follow-up of laboratory abnormalities observed in during 36 month.
12. Maurizio T, Sarzi-Puttini P, Peretti R, et al.: Thrombotic risk factors in primary antiphospholipid syndrome: a 5 year prospective study. Stroke 2005, 36:1490-1494.
13. Groot PG, Derksen RHWM: Antiphospholipid antibodies: update on detection, pathophysiology and treatment. Curr Opin Hematol 2004, 11:165-169. Excellent recent review of the aPL antibodies; detection and treatment.
14. Erkan D, Merrill JT, Yazici Y, et al.: High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001, 44:1466-1467.
15. Ortel TL: Thrombosis and the antiphospholipid syndrome. Hematology. Hematology 2005, 462-468 www.asheducationbook.org/cig/reprint/2005/1/462
16. Brunner HI, Chan WS, Ginsberg JS, et al.: Long term anticoagulation is preferable for patients with antiphospholipid syndrome; result of a decision analysis. J Rheumatol 2002, 29:490-501.
17. Rosove MH, Brewer PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303-330.
18. Crowther MA, Ginsberg JS, Jullian J, et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-1138. Prospective randomized clinical trial comparing the intensity of anticoagulation in patients with APS. In this study 114 patients were enrolled to receive anticoagulation with target INR of either 2.0 to 3.0 or a higher target INR in the range of 3.1 to 4.0. High intensity anticoagulation was not superior as compared with low intensity anticoagulation in preventing recurrent thrombotic events in this study. Patients who had experienced recurrent thrombosis on anticoagulation were excluded from this study.
19. Finazzi G, Marchioli R, Brancaccio V, et al.: A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. J Thrombosis Haemost 2005, 3:848-853. Prospective randomized clinical trial comparing the intensity of anticoagulation in patients with APS. In this study 109 patients were enrolled to received anticoagulation with target INR of either 2.0 to 3.0 or a higher target INR of 3.0 to 4.5. High intensity anticoagulation was not superior as compared with low intensity anticoagulation in preventing recurrent thrombotic events in this study. Patients who had experienced recurrent thrombosis were excluded from this study.
20. Asherson RA, Cervera R, De Groot PG, et al.: Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12:530-534. This paper addresses the rare catastrophic antiphospholipid syndrome. Provides guidelines for recognization, classification and treatment.
21. Asherson RA, Cervera R, Piette JC, et al.: Catastrophic antiphospholipid antibody syndrome. Clinical and laboratory features of 50 patients. Medicine 1998, 77:195-207.
22. Asherson RA, Cervera R, Piette JC, et al.: Catastrophic antiphospholipid antibody syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 2001, 80:355-377.
23. Branch DW, Khamastha MA: Obstetric diagnosis, management and controversies. Obstet Gynecol 2003, 101:1333-1344.
24. Kitridov RC, Goodwin TM: The fetus in systemic lupus erythematosus. In Dubois Lupus, edn 6. Edited by Wallace D, Hahn B. Philadelphia: Lippincott Williams and Wilkins; 2002:1027-1029.
25. Triolo G, Ferrante A, Accardo-Palumbo: IVIG in APS pregnancy. Lupus 2004, 13:731-735.
26. Branch DW, Silver R, Pierangeli S, et al.: Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997, 89:549-555.
27. Cervera R, Balasch J: The management of pregnant patients with antiphospholipid syndrome. Lupus 2004, 13:683-687.
28. Derksen RH, Khamashta MA, Branch DW: Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004, 50:1028-1039. Excellent and detailed review on management of pregnancy in patients with aPL. Exhaustive review of current literature with regards to aPL and obstetric complications.
29. Cowchock FS, Reese EA, Balaban D, et al.: Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 1992, 166:1318-1323.
30. Rai R, Cohen H, Dave M, et al.: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253-257.
31. Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408-413.
32. Noble LS, Kutteh WH, Lashey N, et al.: Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective multicenter controlled pilot study comparing treatment with low molecular weight heparin versus unfractionated heparin. Fertil Steril 2005, 83:684-690.
33. Empson M, Lassere M, Craig J, et al.: Prevention of recurrent miscarriage with antiphospholipid antibody or lupus anticoagulant, (systemic review). Cochrane Database Syst Rev 2005, Volume 4. This is a comprehensive meta-analysis of the major trials in the use of unfractionated heparin and aspirin in the management of recurrent miscarriage, discussing the statistical significance of the combined experience in improving outcomes in this population.
34. Lockshin M, Tenedios F, Petri M, et al.: Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003, 12:518-523.
35. Turiel M, Sarzi-Puttini P, Peretti R, et al.: Five year follow up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 2005, 96:574-579.
36. D'Cruz DP: Renal manifestation of the antiphospholipid syndrome. Lupus 2005, 14:45-48.
37. Korkmaz C, Kabukcuoglu S, Isiksoy S, et al.: Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive treatment. Lupus 2003, 12:760-765.
38. Vaidya S, Sellers R, Kimball P, et al.: Frequency, potential risk and therapeutic intervention in end-stage renal disease. Patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation 2000, 69:1348-1352.
39. Frances C, Niang S, Laffitte E, et al.: Dermatologic manifestation of the antiphospholipid syndrome. Arthritis Rheum 2005, 52:1785-1790.
40. Petri M: Hydroxychloroquine use in the Baltimore lupus cohort: effects of lipids, glucose, and thrombosis. Lupus 1996, 5(Suppl 1):S16-S22.
41. Edwards MH, Pierangeli S, Liu XW, et al.: Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997, 96:4380-4384.
42. Toubi E, Kessel A, Rosner I, et al.: Quinacrine added to ongoing therapeutic regimens attenuates anticardilipin antibody production in SLE. Lupus 2003, 12:297-301.
43. Costedoat-Chalumeau N, Amoura Z, Huong DLT, et al.: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 2005, 4:111-115.
44. Statkute L, Traynor A, Oyama Y, et al.: Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hemotopoietic stem cell transplantation. Blood, prepublished online 5, 2005; DOI 10.1182/blood-2005-01-0330.
45. Ann ER, Lander G, Bidot CJ, et al.: Long term remission from life threatening hypercoagulable state associated with lupus anticoagulant following rituximab therapy. Am J Hematol 2005, 78:127-129.
46. Erkan D, Cervera R, Asherson RA: Catastrophic antiphospholipid syndrome. Where do we stand. Arthritis Rheum 2003, 48:3320-3327.